AI assistant
SELLAS Life Sciences Group, Inc. — Director's Dealing 2010
Jan 19, 2010
33651_dirs_2010-01-19_8fa07374-e98c-4871-b36a-e0a58430fe60.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: RXI PHARMACEUTICALS CORP (RXII)
CIK: 0001390478
Period of Report: 2010-01-14
Reporting Person: Khvorova Anastasia (Chief Science Officer)
Derivative Transactions
| Date | Security | Exercise Price | Code | Shares | A/D | Expiration | Underlying | Ownership |
|---|---|---|---|---|---|---|---|---|
| 2010-01-14 | Stock Option | $5.66 | A | 27182 | Acquired | 2020-01-14 | Common Stock (27182) | Direct |
Footnotes
F1: Granted pursuant to the RXi Pharmaceuticals Corporation 2007 Incentive Plan.
F2: Per share.
F3: The options vest in the following increments on the following dates: 1,698 shares on each of April 14, 2010 and April 14, 2012; and 1,699 shares vest on each of July 14, 2010, October 14, 2010, January 14, 2011, April 14, 2011, July 14, 2011, October 14, 2011, January 14, 2012, July 14, 2012, October 14, 2012, January 14, 2013, April 14, 2013, July 14, 2013, October 14, 2013 and January 14, 2014, with all such options being fully vested on January 14, 2014.